Immuneering Upgraded to Buy: Implications for the Stock

miércoles, 26 de noviembre de 2025, 1:06 pm ET1 min de lectura
IMRX--

Immuneering Corporation (IMRX) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. This reflects the strong correlation between earnings estimate revisions and near-term stock movements. As a result, the company's improving business trend should push the stock higher, making it a solid addition to a portfolio.

Immuneering Upgraded to Buy: Implications for the Stock

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios